Genzyme's Wyntek Buy To Accelerate Point-Of-Care Stroke Test R&D
This article was originally published in The Gray Sheet
Executive Summary
Genzyme General's $65 mil. cash acquisition of rapid point-of-care test developer Wyntek Diagnostics will broaden Genzyme's existing rapid test portfolio and accelerate development of a quantitative rapid stroke panel, Genzyme says. Announced May 8, the deal is expected to close by July 1.